Literature DB >> 21930891

Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis.

P Campoli1, Q Al Abdallah, R Robitaille, N V Solis, J A Fielhaber, A S Kristof, M Laverdiere, S G Filler, D C Sheppard.   

Abstract

Posaconazole prophylaxis has proven highly effective in preventing invasive fungal infections, despite relatively low serum concentrations. However, high tissue levels of this agent have been reported in treated patients. We therefore hypothesized that the intracellular levels of antifungal agents are an important factor in determining the success of fungal prophylaxis. To examine the effect of host cell-associated antifungals on the growth of medically important molds, we exposed cells to antifungal agents and removed the extracellular drug prior to infection. Epithelial cells loaded with posaconazole and its parent molecule itraconazole, but not other antifungals, were able to inhibit fungal growth for at least 48 h and were protected from damage caused by infection. Cell-associated posaconazole levels were 40- to 50-fold higher than extracellular levels, and the drug was predominantly detected in cellular membranes. Fungistatic levels of posaconazole persisted within epithelial cells for up to 48 h. Therefore, the concentration of posaconazole in mammalian host cell membranes mediates its efficacy in prophylactic regimens and likely explains the observed discrepancy between serum antifungal levels and efficacy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930891      PMCID: PMC3232766          DOI: 10.1128/AAC.00637-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity.

Authors:  Leila M Lopes Bezerra; Scott G Filler
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

2.  Use of bimolecular fluorescence complementation to demonstrate transcription factor interaction in nuclei of living cells from the filamentous fungus Acremonium chrysogenum.

Authors:  Birgit Hoff; Ulrich Kück
Journal:  Curr Genet       Date:  2004-11-30       Impact factor: 3.886

3.  A rapid HPLC assay for voriconazole in human plasma.

Authors:  R Gage; D A Stopher
Journal:  J Pharm Biomed Anal       Date:  1998-09       Impact factor: 3.935

4.  Voriconazole therapeutic drug monitoring.

Authors:  J Smith; N Safdar; V Knasinski; W Simmons; S M Bhavnani; P G Ambrose; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

Authors:  Susan J Howard; Jodi M Lestner; Andrew Sharp; Lea Gregson; Joanne Goodwin; Joanne Slater; Jayesh B Majithiya; Peter A Warn; William W Hope
Journal:  J Infect Dis       Date:  2011-02-28       Impact factor: 5.226

6.  Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes.

Authors:  Sofía Ballesta; Isabel García; Evelio J Perea; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2005-04-11       Impact factor: 5.790

7.  Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation.

Authors:  J E Kim; J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

8.  Uptake of Aspergillus fumigatus Conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein.

Authors:  Julie A Wasylnka; Margo M Moore
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

9.  Green fluorescent protein (GFP) as a new vital marker in the phytopathogenic fungus Ustilago maydis.

Authors:  T Spellig; A Bottin; R Kahmann
Journal:  Mol Gen Genet       Date:  1996-10-16

10.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more
  29 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 2.  Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors:  Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal:  Med Mycol       Date:  2019-04-01       Impact factor: 4.076

3.  Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

Authors:  Frederick S Buckner; Julio A Urbina
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-12       Impact factor: 4.077

4.  The management of febrile neutropenia in the posaconazole era: a new challenge?

Authors:  Livio Pagano; Morena Caira; Manuel Cuenca-Estrella
Journal:  Haematologica       Date:  2012-07       Impact factor: 9.941

5.  Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

6.  Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story.

Authors:  Donald C Sheppard; Paolo Campoli; Rafael F Duarte
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 7.  Antifungal stewardship considerations for adults and pediatrics.

Authors:  Rana F Hamdy; Theoklis E Zaoutis; Susan K Seo
Journal:  Virulence       Date:  2016-09-02       Impact factor: 5.882

8.  Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.

Authors:  Jürgen Prattes; Wiebke Duettmann; Martin Hoenigl
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

9.  Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.

Authors:  Shane R Baistrocchi; Mark J Lee; Melanie Lehoux; Benjamin Ralph; Brendan D Snarr; Robert Robitaille; Donald C Sheppard
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

Review 10.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.